Venus Remedies Receives 'Hold' Rating and Shows Strong Financial Performance

Venus Remedies, a microcap pharmaceutical company, has recently received a 'Hold' rating from MarketsMOJO. This upgrade is based on the company's strong ability to service its debt, with an average EBIT to Interest ratio of 11.70. Additionally, the company has shown healthy long-term growth, with an annual operating profit growth rate of 115.00%.
In the last four consecutive quarters, Venus Remedies has declared positive results, with PBT LESS OI(Q) at Rs 5.26 crore, growing at 88.53%, and NET SALES(HY) at Rs 303.77 crore, growing at 21.13%. The company also has a strong cash position, with CASH AND CASH EQUIVALENTS(HY) at its highest at Rs 68.10 crore.

With a ROE of 5.8, Venus Remedies has a very attractive valuation with a 1 Price to Book Value. The stock is currently trading at a fair value compared to its average historical valuations. In the past year, the stock has generated a return of 29.66%, while its profits have risen by 36.7%. The PEG ratio of the company is 0.5, indicating a potential undervaluation.

Majority shareholders of Venus Remedies are non-institutional investors. Technically, the stock is currently in a mildly bearish range, with both MACD and KST technical factors also showing a bearish trend. Overall, with its strong financials and potential undervaluation, Venus Remedies is a stock to watch in the pharmaceutical industry.